Highly active antiretroviral treatments (HAART) have transformed HIV infection from a deadly disease into a manageable chronic condition. As a consequence, HIV-infected individuals live longer and the proportion of older individuals within the HIV infected population is constantly growing. Thus, the management of HIV infection is becoming more complex as patients encounter more age related chronic but also severe morbidities, leading to polypharmacy and consequently to potential drug-drug interactions (DDIs).
We aim to determine the magnitude of DDIs between antiretroviral drugs and commonly prescribed co-medications (e.g. amlodipine, rosuvastatin and atorvastatin) in HIV-infected patients of the SHCS. For that purpose, we conduct pharmacokinetic investigations in patients treated with a darunavir/ritonavir- or a dolutegravir-containing regimen and who receive one of the cardiovascular drug of interest. Eligible patients will undergo a pharmacokinetic investigation while treated with darunavir/ritonavir (strong inhibitor of drug metabolizing enzymes) and dolutegravir (no inhibitory effect on drug metabolizing enzymes) in order to determine the magnitude of the interaction with the co-medication.
Results from this study will be available after study completion.
The study has been approved by the Ethics Committee Vaud and the Ethics Committee northwest/central Switzerland EKNZ.
Swiss National Science Foundation, grants N° 324730-165956 and 324730_166204.